Irene Cecchi

TL;DR: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option and an improvement in respiratory and laboratory parameters was observed, requiring future controlled trials to confirm the definite benefit with IL-6 target therapy.

TL;DR: The pathogenic role of neutrophils in RA, the effect of conventional treatments and biologic therapies, and the new, potential targets of neutophil-derived molecules for the treatment of RA are reviewed.

TL;DR: In this paper, the authors conducted a literature search to identify articles reporting clinical experience with the use of eculizumab in SLE patients, focusing on renal involvement, and reported promising results.

TL;DR: The results highlight the potential of Qred to modulate the overexpression of inflammatory and thrombotic risk markers in APS and suggest it might act as safe adjunct to standard therapies in APs.

TL;DR: An overall estimated median prevalence of anti‐&bgr;2 GPI‐DI antibodies of 44.3% is reported in patients with APS and/or SLE and a significantly higher prevalence among patients withAPS compared with SLE alone, which might represent a promising tool when assessing thrombotic risk in patientsWith APS.